检索范围:
排序: 展示方式:
The epidemic status and risk factors of lung cancer in Xuanwei City, Yunnan Province, China
null
《医学前沿(英文)》 2012年 第6卷 第4期 页码 388-394 doi: 10.1007/s11684-012-0233-3
Xuanwei City (formerly known as Xuanwei County) locates in the northeastern of Yunnan Province and is rich in coal, iron, copper and other mines, especially the smoky (bituminous) coal. Unfortunately, the lung cancer morbidity and mortality rates in this region are among China’s highest, with a clear upward trend from the mid-1970s to mid-2000s. In 2004–2005, the crude death rate of lung cancer was 91.3 per 100 000 in the whole Xuanwei City, while that for Laibin Town in this city was 241.14 per 100 000. The epidemiologic distribution (clustering patterns by population, time, and space) of lung cancer in Xuanwei has some special features, e.g., high incidence in rural areas, high incidence in females, and an early age peak in lung cancer deaths. The main factor that associates with a high rate of lung cancer incidence was found to be indoor air pollution caused by the indoor burning of smoky coal. To a certain extent, genetic defects are also associated with the high incidence of lung cancer in Xuanwei. Taken together, lung cancer in this smoky coal combustion region is a unique model for environmental factor-related human cancer, and the current studies indicate that abandoning the use of smoky coal is the key to diminish lung cancer morbidity and mortality.
关键词: lung cancer Xuanwei smoky coal combustion polycyclic aromatic hydrocarbons epidemiology
《医学前沿(英文)》 2023年 第17卷 第4期 页码 714-728 doi: 10.1007/s11684-022-0959-5
关键词: FRMD6 lung cancer mTOR pathway
《医学前沿(英文)》 2023年 第17卷 第1期 页码 18-42 doi: 10.1007/s11684-022-0976-4
关键词: non-small cell lung cancer driver mutations treatment strategy resistant mechanism immune-checkpoint inhibitors
Pathogenesis sequences in Gejiu miners with lung cancer: an introduction
null
《医学前沿(英文)》 2015年 第9卷 第3期 页码 344-349 doi: 10.1007/s11684-015-0399-6
Tin miners in Gejiu, Yunnan Province, China are at high risk of developing lung cancer with significant occupational characteristics. Tissue samples from these miners presented pathological characteristics, such as fibroplasia in carcinomas, peri-cancerous tissue in lung cancers, and hyperplasia and dysplasia of epithelial cells in peri-cancerous tissue. Carcinomas induced by Yunnan tin mine dust in the animal experiment underwent inflammation, fibroplasia, hyperplasia, dysplasia, and carcinogenesis of epithelial cells. A correlated and synergistic relationship was observed between bronchial epithelial cell transformation and fibroblast activation in vitro induced by mine dust. Fibroblast hyperplasia and activation are important factors that promote the transformation and carcinogenesis of epithelial cells. Our findings suggested that pulmonary fibrosis may increase the risk and promote the occurrence of lung cancer, which can lead to lung fiber hyperplasia.
Curbing the burden of lung cancer
null
《医学前沿(英文)》 2016年 第10卷 第2期 页码 228-232 doi: 10.1007/s11684-016-0447-x
Lung cancer contributes substantially to the global burden of disease and healthcare costs. New screening modalities using low-dose computerized tomography are promising tools for early detection leading to curative surgery. However, the screening and follow-up diagnostic procedures of these techniques may be costly. Focusing on prevention is an important factor to reduce the burden of screening, treatment, and lung cancer deaths. The International Agency for Research on Cancer has identified several lung carcinogens, which we believe can be considered actionable when developing prevention strategies. To curb the societal burden of lung cancer, healthcare resources need to be focused on early detection and screening and on mitigating exposure(s) of a person to known lung carcinogens, such as active tobacco smoking, household air pollution (HAP), and outdoor air pollution. Evidence has also suggested that these known lung carcinogens may be associated with genetic predispositions, supporting the hypothesis that lung cancers attributed to differing exposures may have developed from unique underlying genetic mechanisms attributed to the exposure of interest. For instance, smoking-attributed lung cancer involves novel genetic markers of risk compared with HAP-attributed lung cancer. Therefore, genetic risk markers may be used in risk stratification to identify subpopulations that are at a higher risk for developing lung cancer attributed to a given exposure. Such targeted prevention strategies suggest that precision prevention strategies may be possible in the future; however, much work is needed to determine whether these strategies will be viable.
Orlistat induces ferroptosis-like cell death of lung cancer cells
《医学前沿(英文)》 2021年 第15卷 第6期 页码 922-932 doi: 10.1007/s11684-020-0804-7
Low-dose CT for lung cancer screening: opportunities and challenges
null
《医学前沿(英文)》 2018年 第12卷 第1期 页码 116-121 doi: 10.1007/s11684-017-0600-1
Lung cancer is among the most frequently diagnosed cancers worldwide and the leading cause of cancer death in both males and females. Screening for lung cancer coupled with earlier intervention has long been studied as an approach to mortality reduction. However, minimal progress was achieved until recently, when low-dose spiral computed tomography (LDCT) screening demonstrated a 20% reduction in mortality from lung cancer in a randomized controlled trial (RCT), the National Lung Screening Trial, from the United States. On the basis of this finding, LDCT has been recommended for lung cancer screening in high-risk populations by several clinical guidelines. However, results from the following independent RCTs in Europe failed to show consistent conclusions. In addition, intractable problems gradually emerged with the progress of LDCT screening. This paper summarizes and discusses the main observations and challenges of LDCT screening for lung cancer. Before spreading implementation of LDCT screening, challenges, including high false-positive rates, overdiagnosis, enormous costs, and radiation risk, must be addressed. Complementary biomarkers and technical improvement are expected in the field of lung cancer screening in the near future.
关键词: lung cancer low-dose computerized tomography early detection opportunities challenges
Molecular markers and pathogenically targeted therapy in non-small cell lung cancer
Bo PENG BA , Jinnong ZHANG MD , Jamile S. WOODS MD , Wei PENG MD, PhD
《医学前沿(英文)》 2009年 第3卷 第3期 页码 245-255 doi: 10.1007/s11684-009-0044-3
关键词: lung cancer carcinoma non-small cell lung cancer molecular markers targeted therapy
Four-protein model for predicting prognostic risk of lung cancer
《医学前沿(英文)》 2022年 第16卷 第4期 页码 618-626 doi: 10.1007/s11684-021-0867-0
Anlotinib as third- or further-line therapy for short-term relapsed small-cell lung cancer: subgroup
《医学前沿(英文)》 2022年 第16卷 第5期 页码 766-772 doi: 10.1007/s11684-021-0916-8
关键词: anlotinib chemotherapy short-term relapsed small-cell lung cancer
null
《医学前沿(英文)》 2013年 第7卷 第2期 页码 157-171 doi: 10.1007/s11684-013-0272-4
Non-small-cell lung cancer (NSCLC) is the most common cause of premature death among the malignant diseases worldwide. The current staging criteria do not fully capture the complexity of this disease. Molecular biology techniques, particularly gene expression microarrays, proteomics, and next-generation sequencing, have recently been developed to facilitate effectively its molecular classification. The underlying etiology, pathogenesis, therapeutics, and prognosis of NSCLC based on an improved molecular classification scheme may promote individualized treatment and improve clinical outcomes. This review focuses on the molecular classification of NSCLC based on gene expression microarray technology reported during the past decade, as well as their applications for improving the diagnosis, staging and treatment of NSCLC, including the discovery of prognostic markers or potential therapeutic targets. We highlight some of the recent studies that may refine the identification of NSCLC subtypes using novel techniques such as epigenetics, proteomics, or deep sequencing.
关键词: non-small-cell lung cancer molecular typing individualized medicine molecular-targeted therapy gene expression profiling
MicroRNAs and lung cancers: from pathogenesis to clinical implications
null
《医学前沿(英文)》 2012年 第6卷 第2期 页码 134-155 doi: 10.1007/s11684-012-0188-4
Lung cancer is the leading cause of cancer-related deaths in the US and worldwide. Better understanding of the disease is warranted for improvement in clinical management. Here we summarize the functions of small-RNA-based, posttranscriptional gene regulators, i.e. microRNAs, in the pathogenesis of lung cancers. We discuss the microRNAs that play oncogenic as well as tumor suppressive roles. We also touch on the value of microRNAs as markers for diagnosis, prognosis and the promising field of microRNA-based novel therapies for lung cancers.
《医学前沿(英文)》 2022年 第16卷 第4期 页码 610-617 doi: 10.1007/s11684-021-0827-8
关键词: bevacizumab elderly patient advanced non-small-cell lung cancer overall survival toxicity
Functional XPF polymorphisms associated with lung cancer susceptibility in a Chinese population
Dian-Ke YU PhD, Chen WU MD, Wen TAN MD, Dong-Xin LIN MD,
《医学前沿(英文)》 2010年 第4卷 第1期 页码 82-89 doi: 10.1007/s11684-010-0014-9
关键词: XPF polymorphism lung cancer
Chimeric antigen receptor T cell targeting EGFRvIII for metastatic lung cancer therapy
Zhao Zhang, Jun Jiang, Xiaodong Wu, Mengyao Zhang, Dan Luo, Renyu Zhang, Shiyou Li, Youwen He, Huijie Bian, Zhinan Chen
《医学前沿(英文)》 2019年 第13卷 第1期 页码 57-68 doi: 10.1007/s11684-019-0683-y
Lung cancer is the most common incident cancer and the leading cause of cancer death. In recent years, the development of tumor immunotherapy especially chimeric antigen receptor T (CAR-T) cell has shown a promising future. Epidermal growth factor receptor variant III (EGFRvIII) is a tumor-specific mutation expressed in various types of tumors and has been detected in non-small cell lung cancer with a mutation rate of 10%. Thus, EGFRvIII is a potential antigen for targeted lung cancer therapy. In this study, CAR vectors were constructed and transfected into virus-packaging cells. Then, activated T cells were infected with retrovirus harvested from stable virus-producing single clone cell lines. CAR expression on the surfaces of the T cells was detected by flow cytometry and Western blot. The function of CAR-T targeting EGFRvIII was then evaluated. The EGFRvIII-CAR vector was successfully constructed and confirmed by DNA sequencing. A stable virus-producing cell line was produced from a single clone by limited dilution. The culture conditions for the cell line, including cell density, temperature, and culture medium were optimized. After infection with retrovirus, CAR was expressed on more than 90% of the T cells. The proliferation of CAR-T cells were induced by cytokine and specific antigen in vitro. More importantly, EGFRvIII-CART specifically and efficiently recognized and killed A549-EGFRvIII cells with an effector/target ratio of 10:1 by expressing and releasing cytokines, including perforin, granzyme B, IFN-g, and TNF-α. The in vivo study indicated that the metastasis of A549-EGFRvIII cells in mice were inhibited by EGFRvIII-CART cells, and the survival of the mice was significantly prolonged with no serious side effects. EGFRvIII-CART showed significantly efficient antitumor activity against lung cancer cells expressing EGFRvIII in vivo and in vitro. Therefore, CAR-T targeting EGFRvIII is a potential therapeutic strategy in preventing recurrence and metastasis of lung cancer after surgery.
关键词: chimeric antigen receptor T cells epidermal growth factor receptor lung cancer immunotherapy tumor immunology
标题 作者 时间 类型 操作
The epidemic status and risk factors of lung cancer in Xuanwei City, Yunnan Province, China
null
期刊论文
FERM domain-containing protein FRMD6 activates the mTOR signaling pathway and promotes lung cancer progression
期刊论文
Treatment of advanced non-small cell lung cancer with driver mutations: current applications and future
期刊论文
Molecular markers and pathogenically targeted therapy in non-small cell lung cancer
Bo PENG BA , Jinnong ZHANG MD , Jamile S. WOODS MD , Wei PENG MD, PhD
期刊论文
Anlotinib as third- or further-line therapy for short-term relapsed small-cell lung cancer: subgroup
期刊论文
Molecular classification of non-small-cell lung cancer: diagnosis, individualized treatment, and prognosis
null
期刊论文
combination with pemetrexed and platinum for elderly patients with advanced non-squamous non-small-cell lungcancer: a retrospective analysis
期刊论文
Functional XPF polymorphisms associated with lung cancer susceptibility in a Chinese population
Dian-Ke YU PhD, Chen WU MD, Wen TAN MD, Dong-Xin LIN MD,
期刊论文